beta-Bourbonene is a sesquiterpene hydrocarbon reported in spearmint, amla, Betonica, and other plant volatile profiles. The strongest direct constituent literature located in this pass is still preclinical: one open-access cell paper reported antiproliferative and apoptosis-related effects in a prostate-cancer cell model, while broader occurrence papers mostly document beta-bourbonene as a minor-to-secondary GC/MS marker rather than a clinically established active. For AromaForge, it is best presented as a chemistry-first constituent with limited standalone pharmacology and no basis for medical claims.
Chemical identity and composition
PubChem resolves beta-bourbonene to CID 62566 with formula C15H24 and a tricyclic sesquiterpene structure. PubChem synonyms and the NIST WebBook both support CAS 5208-59-3. In the local archive, beta-bourbonene is already documented in two spearmint records, including 2.29% in one Shay and Company GC/MS report and 1.13% in a separate commercial spearmint analysis.
Aroma and practical use
- Use the recorded woody, terpenic, green, mint-supporting descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2018 open-access Oncology Letters paper reported that beta-bourbonene inhibited PC-3M prostate-cancer cell growth in a dose-dependent manner, induced G0/G1 arrest, and increased apoptosis in vitro.
A 2018 open-access Oncology Letters paper reported that beta-bourbonene inhibited PC-3M prostate-cancer cell growth in a dose-dependent manner, induced G0/G1 arrest, and increased apoptosis in vitro.
This experimental finding does not establish benefit, dose or safety in people using this blend.
The same 2018 paper reported increased Fas and FasL mRNA expression plus higher Bax and lower Bcl-2 protein expression after beta-bourbonene exposure in PC-3M cells.
The same 2018 paper reported increased Fas and FasL mRNA expression plus higher Bax and lower Bcl-2 protein expression after beta-bourbonene exposure in PC-3M cells.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2009 Phyllanthus emblica volatile-oil paper identified beta-bourbonene among the main components of both fruit and leaf oils and reported broad-spectrum antimicrobial activity for the oils, but not for isolated beta-bourbonene alone.
A 2009 Phyllanthus emblica volatile-oil paper identified beta-bourbonene among the main components of both fruit and leaf oils and reported broad-spectrum antimicrobial activity for the oils, but not for isolated beta-bourbonene alone.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific IFRA limit, RIFM safety assessment, or human tolerability study for isolated beta-bourbonene was located in the reviewed public sources.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The strongest direct activity evidence located for beta-bourbonene is limited to cell research, so archive copy should avoid anticancer or therapeutic claims.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
fas fasl and bax bcl2 apoptosis signal
In one PC-3M cell paper, beta-bourbonene was associated with higher Fas, FasL, and Bax expression together with lower Bcl-2 expression, consistent with apoptosis-related signaling in that model.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
no human validated mechanism
No constituent-specific human pharmacology or clinically validated mechanism for isolated beta-bourbonene was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No human clinical studies specific to isolated beta-bourbonene were located in the reviewed public sources.
- The strongest direct bioactivity evidence found for beta-bourbonene is limited to one cell-culture paper.
- No IFRA Standard, RIFM fragrance ingredient safety assessment, or Tisserand & Young monograph specific to beta-bourbonene (CAS 5208-59-3) was located after a dedicated safety-focused search pass; a dermal limit percentage was not invented and dermal_limit_verified remains false.
- Constituent-specific dermal sensitization and phototoxicity data for isolated beta-bourbonene remain unverified.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.